Expanding Clinical Pipelines, Contract Manufacturing Adoption, and Automation-Led Process Innovation Fuel Robust Market Growth Globally.Austin, United States, Feb. 27, 2026 (GLOBE NEWSWIRE) -- ...

CAMBRIDGE, England & BAD HOMBURG, Germany--(BUSINESS WIRE)--Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that ...

SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...

TOKYO--(BUSINESS WIRE)--PHC Corporation Biomedical Division (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura, hereinafter referred to as "Biomedical Division") will showcase a prototype ...

A study has developed an innovative method that overcomes the limitations of traditional additive manufacturing (3D printing), significantly simplifying and accelerating the production of ...

This article aims to explain the current landscape of cell therapy manufacturing, including its challenges and solutions.

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an ...

- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions - In the pharmaceutical industry, the ...

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...

A study led by the School of Engineering of the Hong Kong University of Science and Technology (HKUST) has developed an innovative method that overcomes the limitations of traditional additive ...